Are Accuray, Boston Scientific, and Opko Health Creating Top-Line Products?
New York, NY – GDP INSIDER – 10/08/2014.
This article discusses three medical companies that recently released reports regarding their the success of their testing: Accuray, Boston Scientific, and Opko Health.
Accuray Incorporated(NASDAQ:ARAY) currently has a bid price of $3.69 x 1,000 and an offer price of $8.99 x 4,200, figures that should be troubling to shareholders and prospective investors of the California-based radiosurgery and radiation therapy systems designer. Nevertheless, the California-based company did receive a piece of good news when it announced at the ASTRO meeting in San Francisco that studies had shown its TomoTherapy system to improve tumor control with reduced toxicities in breast cancer patients.
On Wednesday, the Boston Scientific Corporation(NYSE:BSX) will have its Watchman device reviewed for the third time by the FDA’s Circulatory System Devices advisory panel. Even if the Watchman is not successful, potential investors of the company will want to take note of the Massachusetts-based innovative medical solutions company’s REPRISE III clinical trail on Lotus Valve System’s effectiveness. The product is a transcatheter aortic valve replacement device that is both repositionable and retrievable.
Opko Helath Inc.(NYSE:OPK) announced on Sept. 23rd that its final phase 3 trial of Rayaldee had met its primary endpoints. As a result, the Miamai-based company will be submitting a new drug application submission to the United States Food and Drug Administration. The product would be used as a treatment for secondary hyperparathyroidism in patients with both chronic kidney disease and vitamin D insufficiency. The company has a market capitalizaiton of $3.59 billion.
HotStockGains.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word BREAKOUT to 555888 from your cell phone.
Additionally, HotStockGains free newsletter provides market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks.
Disclosure: HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit http://hotstockgains.com/disclaimer/ for complete risks and disclosures.